NASDAQ:AKRXAkorn Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Akorn.

Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings results on Monday, May, 11th. The company reported $0.36 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.45. The business earned $204.69 million during the quarter, compared to analysts' expectations of $168.90 million. Akorn had a positive return on equity of 8.53% and a negative net margin of 55.64%. View Akorn's earnings history.

2 brokerages have issued 1-year price objectives for Akorn's shares. Their forecasts range from $2.00 to $4.00. On average, they expect Akorn's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 873.1% from the stock's current price. View analysts' price targets for Akorn.

Headlines about AKRX stock have been trending very negative on Monday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Akorn.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn's stock is owned by many different retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.38%). Company insiders that own Akorn stock include Alan D Weinstein, Christopher Young, Jonathan Kafer, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View institutional ownership trends for Akorn.

AKRX stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer, and Terry Allison Rappuhn. View insider buying and selling activity for Akorn.

One share of AKRX stock can currently be purchased for approximately $0.31.

Akorn has a market capitalization of $41.05 million and generates $682.43 million in revenue each year. The company earns $-226,770,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Akorn employs 2,227 workers across the globe.

The official website for Akorn is www.akorn.com.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]